Stockreport

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual M...

Clene Inc.  (CLNN) 
PDF Significantly improved clinical outcomes associated with long-term daily oral CNM-Au8 ® 30 mg treatment (change from original baseline; p Long-term CNM-Au8 treatment, [Read more]